AstraZeneca stock edges lower ahead of the open after Imfinzi trial win
Published on 09/09/2026 at 08:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock closed at about USD 161.50 on its US listing on September 8, 2026, down roughly 0.7 percent from the prior session. The move left the shares trailing the broader market less severely than the S&P 500, which dropped about 1.2 percent on the same day. Investors balanced profit taking against positive oncology news, including a landmark survival result for the Imfinzi combination and recent US approval for the Etcamah breast cancer pill.
September 8, 2026 in numbers
AstraZeneca PLC (ISIN US6549022043, NYSE: AZN) saw its US shares end around USD 161.50 on September 8, 2026, after trading within a session range that kept the close near the lower half of the day’s band per NYSE data. The roughly 0.7 percent decline came against a backdrop of a wider equity pullback, with the Dow Jones Industrial Average sliding about 1.2 percent and the S&P 500 also losing around 1.2 percent. According to Yahoo Finance, AstraZeneca’s US shares fell to roughly USD 161.51 on September 8, 2026 even as the company reported that its cancer drug Imfinzi, combined with Amgen’s Imdelltra, significantly extended survival in first-line extensive-stage small-cell lung cancer in a late-stage trial.
The oncology pipeline remained in focus beyond Imfinzi. As Bloomberg reported on September 8, 2026, the US Food and Drug Administration recently approved AstraZeneca’s oral breast cancer medicine camizestrant, to be marketed as Etcamah, which the company believes could eventually exceed USD 5 billion in annual sales. A broader wrap by Ground News on September 9, 2026 highlighted the FDA’s accelerated approval for Etcamah in certain advanced breast cancer patients, underlining how recent regulatory milestones are shaping sentiment around AstraZeneca’s oncology franchise even as the share price paused after its latest run.
Today’s focus for AstraZeneca
Today, attention around AstraZeneca is set to stay on its expanding oncology portfolio and investor discussions of valuation. A recent analysis by GuruFocus on September 8, 2026 argued that AstraZeneca shares around USD 162.70 traded approximately 10.1 percent below an estimated GF Value of USD 180.91, framing the stock as modestly undervalued on historical multiples and projected earnings while emphasizing the sustainability of its dividend. Against this backdrop, traders heading into today’s US session are expected to watch for further reactions to the Imfinzi survival data, the Etcamah approval and any additional trial or regulatory updates that could alter perceptions of the company’s long-term growth path.
